Incidence and long-term survival of patients with de-novo head and neck carcinoma after liver transplantation.

BackgroundLiver transplant recipients have an increased risk of developing de novo malignancies. MethodsWe conducted a prospective evaluation of clinicopathological data and predictors for overall survival (OS) in patients with head and neck squamous cell carcinoma (HNSCC) after liver transplantation (1988 to 2010). ResultsThirty-three of 2040 patients who underwent liver transplantation (1.6%) developed de novo HNSCC. The incidence of HNSCC in liver transplant recipients with end-stage alcoholic liver disease (26) was 5%. After a median follow-up of 9 years, 1-year, 3-year, and 5-year OS rates were 74%, 47%, and 34%, respectively. Tumor size, cervical lymph node metastases, tumor site, and therapy (surgery only vs surgery and adjuvant radiotherapy [RT]/chemoradiotherapy [CRT] vs RT/CRT only; p<.0001) were significantly associated with OS in univariate analysis. However, surgery only predicted OS independently in multivariate analysis. ConclusionEarly diagnosis and surgical treatment of de novo HNSCC are crucial to the outcome. HNSCC risk should be taken into close consideration during posttransplantation follow-up examinations, especially among patients with a positive history of smoking and alcohol consumption. (c) 2015 Wiley Periodicals, Inc. Head Neck 38: 707-714, 2016